Cited by 5,228Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver physiology and pathology

The DOI matches its Crossref record; 90 of the 92 references it cites were found in a registry or an index, and 2 are not checked yet.

Nonalcoholic Fatty Liver Disease

Angulo, Paul·2002·New England Journal of Medicine

DOI 10.1056/nejmra011775

Open this paper in CoChat — free account

Abstract

Alcohol abuse is the most common cause of fatty liver disease, but it is now apparent that fat deposition in the liver, and its consequences, may occur without alcohol abuse. The principal risk factors are obesity, non-insulin-dependent diabetes mellitus, and hyperlipidemia. The disorder has a wide clinical spectrum, ranging from asymptomatic steatosis to steatohepatitis, fibrosis, and cirrhosis. This article provides a broad overview of this increasingly recognized liver disease.

Integrity signals

Registry

Crossref · 10.1056/nejmra011775

Cites

90 of 92 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
Esterbauer, H., Schaur, R. J., & Zollner, H. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90192-6 · Cited by 6,672
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon‐Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,973
Nonalcoholic Steatohepatitis
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078

Show all 90 references

Research works printed but not linked: 9

Schaffner F, 1986, Prog Liver Dis, 8, 283
Itoh S, 1987, Am J Gastroenterol, 82, 650
Silverman JF, 1990, Am J Gastroenterol, 85, 1349
Creutzfeldt W, 1970, Prog Liver Dis, 3, 371
Silverman JF, 1989, Pathol Annu, 24, 275
Debaere C, 1998, J Belge Radiol, 81, 174
Zatloukal K, 1991, Lab Invest, 64, 200
Curzio M, 1985, Int J Tissue React, 7, 137
Watson AM, 1999, Drug Metab Dispos, 27, 695

Sorted by citations

Items 301–400 of 1,031

Temporal Trends of Nonalcoholic Fatty Liver Disease–Related Hepatocellular Carcinoma in the Veteran Affairs Population
Mittal, S., Sada, Y. H., El‐Serag, H. B., Kanwal, F., Duan, Z., Temple, S., May, S., Kramer, J. R., Richardson, P., & Davila, J. A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.013 · Cited by 269
Association of Cardiorespiratory Fitness, Body Mass Index, and Waist Circumference to Nonalcoholic Fatty Liver Disease
Church, T. S., Kuk, J. L., Ross, R., Priest, E. L., Biltoff, E., & Blair, S. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.019 · Cited by 268
VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet‐induced nonalcoholic steatohepatitis model in mice†
Velayudham, A., Dolganiuc, A., Ellis, M., Petrášek, J., Kodys, K., Mandrekar, P., & Szabó, G. (2008) · Hepatology · doi:10.1002/hep.22711 · Cited by 268
Nonalcoholic Fatty Liver Disease: A Clinical Review
Sass, D. A., Chang, P., & Chopra, K. B. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-1267-z · Cited by 267
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
Pagano, C., Soardo, G., Esposito, W., Fallo, F., Basan, L., Donnini, D., Federspil, G., Sechi, L. A., & Vettor, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01821 · Cited by 266
Pathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 266
Adiponectin, a key adipokine in obesity related liver diseases.
Buechler, C., Wanninger, J., & Neumeier, M. (2011) · PubMed · doi:10.3748/wjg.v17.i23.2801 · Cited by 264
Prevention Conference VII
Caterson, I. D., Hubbard, V. S., Bray, G. A., Grunstein, R. R., HANSEN, B. C., Hong, Y., Labarthe, D. R., Seidell, J. C., & Smith, S. C. (2004) · Circulation · doi:10.1161/01.cir.0000140114.83145.59 · Cited by 264
Unanswered Questions — Drug-Eluting Stents and the Risk of Late Thrombosis
Maisel, W. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068305 · Cited by 263
Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis , , ,
Chung, M., Ma, J., Patel, K., Berger, S. E., Lau, J. S. M., & Lichtenstein, A. H. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.086314 · Cited by 263
Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis
Akazawa, Y., Cazanave, S. C., Mott, J. L., Elmi, N. A., Bronk, S. F., Kohno, S., Charlton, M., & Gores, G. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.003 · Cited by 262
Advances in Pediatric Nonalcoholic Fatty Liver Disease†
Loomba, R. S., Sirlin, C. B., Schwimmer, J. B., & Lavine, J. E. (2009) · Hepatology · doi:10.1002/hep.23119 · Cited by 262
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Fernández‐Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solis-Herruzo, J. A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.002 · Cited by 262
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease
Choi, S. S., & Diehl, A. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ff5e55 · Cited by 261
Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study
Koehler, E. M., Schouten, J. N. L., Hansen, B. E., van Rooij, F. J. A., Albert Hofman, D., Stricker, B. H. C., & Janssen, H. L. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.028 · Cited by 261
Visceral fat and liver fat are independent predictors of metabolic risk factors in men
Nguyen-Duy, T.-B., Nichaman, M. Z., Church, T. S., Blair, S. N., & Ross, R. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00442.2002 · Cited by 260
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications
Alkhouri, N., Carter-Kent, C. A., & Feldstein, A. E. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.6 · Cited by 259
Non-invasive means of measuring hepatic fat content
Mehta, S. R., Thomas, E. L., Bell, J. D., Johnston, D. G., & Taylor-Robinson, S. D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3476 · Cited by 259
Metabolic disturbances in non-alcoholic fatty liver disease
Byrne, C. D., Olufadi, R., Bruce, K. D., Cagampang, F. R. A., & Ahmed, M. H. (2009) · Clinical Science · doi:10.1042/cs20080253 · Cited by 258
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Pasternak, R. C., Smith, S. C., Merz, C. N. B., Grundy, S. M., Cleeman, J. I., & Lenfant, C. J. M. (2002) · Stroke · doi:10.1161/01.str.0000034125.94759.41 · Cited by 257
MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis
Ogawa, T., Enomoto, M., Fujii, H., Sekiya, Y., Yoshizato, K., Ikeda, K., & Kawada, N. (2012) · Gut · doi:10.1136/gutjnl-2011-300717 · Cited by 257
Association Between Elevated Liver Enzymes and C-Reactive Protein
Kerner, A., Avizohar, O., Sella, R., Bartha, P., Zinder, O., Markiewicz, W., Levy, Y., Brook, G. J., & Aronson, D. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000148324.63685.6a · Cited by 257
Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study
Askgaard, G., Grønbæk, M., Kjær, M. S., Tjønneland, A., & Tolstrup, J. S. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.005 · Cited by 256
Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle
Barazzoni, R., Bosutti, A., Stebel, M., Cattin, M. R., Roder, E., Visintin, L., Cattin, L., Biolo, G., Zanetti, M., & Guarnieri, G. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00115.2004 · Cited by 256
Hepatic Steatosis (Fatty Liver Disease) in Asymptomatic Adults Identified by Unenhanced Low-Dose CT
Boyce, C. J., Pickhardt, P. J., Kim, D. H., TAYLOR, A. J., Winter, T. C., Bruce, R. J., Lindstrom, M. J., & Hinshaw, J. L. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.2590 · Cited by 256
Fatty liver index and mortality: The cremona study in the 15th year of follow-up
Calori, G., Lattuada, G., Ragogna, F., Garancini, M. P., Crosignani, P., Villa, M., Bosi, E., Ruotolo, G., Piemonti, L., & Perseghin, G. (2011) · Hepatology · doi:10.1002/hep.24356 · Cited by 256
Small Nucleolar RNAs U32a, U33, and U35a Are Critical Mediators of Metabolic Stress
Michel, C. I., Holley, C. L., Scruggs, B. S., Sidhu, R., Brookheart, R. T., Listenberger, L. L., Behlke, M. A., Ory, D. S., & Schaffer, J. E. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.009 · Cited by 254
Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis
George, J., Pera, N., Phung, N., Leclercq, I. A., Hou, J. Y., & Farrell, G. C. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00376-3 · Cited by 253
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction
Adams, L. A., Feldstein, A. E., Lindor, K. D., & Angulo, P. (2004) · Hepatology · doi:10.1002/hep.20140 · Cited by 252
Self-citation
Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions
Adolph, T. E., Grander, C., Grabherr, F., & Tilg, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081649 · Cited by 252
Non Alcoholic Fatty Liver: Epidemiology and Natural History
Masarone, M., Federico, A., Abenavoli, L., Loguercio, C., & Persico, M. (2015) · Reviews on Recent Clinical Trials · doi:10.2174/1574887109666141216111143 · Cited by 250
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249
Liver diseases and aging: friends or foes?
Sheedfar, F., Biase, S. D., Koonen, D. P. Y., & Vinciguerra, M. (2013) · Aging Cell · doi:10.1111/acel.12128 · Cited by 249
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease
Obika, M., & Noguchi, H. (2011) · Experimental Diabetes Research · doi:10.1155/2012/145754 · Cited by 249
Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway
Cao, J., Dai, D.-L., Long, Y., Yu, H., Ning, B., Zhang, Q., Chen, J., Cheng, W., Shen, W., & Yang, Z. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1211-9 · Cited by 248
The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil
Ditano-Vázquez, P., Torres-Peña, J. D., Valle, F. G., Pérez-Caballero, A. I., Rodríguez, P. D., López‐Miranda, J., Katsiki, N., Delgado‐Lista, J., & Alvarez-Sala-Walther, L. A. (2019) · Nutrients · doi:10.3390/nu11112833 · Cited by 248
Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu, I., & Brunt, E. M. (2014) · PubMed · doi:10.3748/wjg.v20.i27.9026 · Cited by 247
Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis
Leroux, A., Ferrere, G., Godie, V., Cailleux, F., Renoud, M.-L., Gaudin, F., Naveau, S., Prévot, S., Makhzami, S., Perlemuter, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.028 · Cited by 246
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice
Fu, J., Gerhardt, H., McDaniel, J. M., Xia, B., Liu, X., Ivanciu, L., Ny, A., Hermans, K., Silasi‐Mansat, R., McGee, S., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36077 · Cited by 246
Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain
Caballería, L., Pera, G., Auladell, M. A., Torán‐Monserrat, P., Muñoz, L., Miranda, D., Alumà, A., Casas, J. D., Sánchez, C., Gil, D., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832fcdf0 · Cited by 246
Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease
Videla, L. A., Rodrigo, R., Julia Araya, A., & Poníachik, J. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.06.033 · Cited by 245
Specific Contribution of Methionine and Choline in Nutritional Nonalcoholic Steatohepatitis
Caballero, F., Fernández, A., Matías, N., Martínez-Gili, L., Fucho, R., Elena, M., Caballería, J., Morales, A., Fernández-Checa, J. C., & García‐Ruiz, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.099333 · Cited by 245
A major health hazard: The metabolic syndrome
Isomaa, B. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00646-5 · Cited by 245
Nonalcoholic Fatty Liver Disease in HIV‐Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors
Guaraldi, G., Squillace, N., Stentarelli, C., Orlando, G., D’Amico, R., Ligabue, G., Fiocchi, F., Zona, S., Loria, P., Esposito, R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589294 · Cited by 244
Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation
Andrade, J. M. O., Paraíso, A. F., de Oliveira, M. V. M., Martins, A. M. E. D. B. L., Neto, J. F. R., Guimarães, A. L. S., de Paula, A. M., Qureshi, M. H., & Santos, S. H. S. (2013) · Nutrition · doi:10.1016/j.nut.2013.11.016 · Cited by 243
Adverse effects of dietary fructose.
Gaby, A. R. (2005) · PubMed · Cited by 243
Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases*
Min De, Z. E. N. G., Fan, J., Lu, L., You Ming, L. I., Cheng Wei, C. H. E. N., Wang, B. Y., & Ma, H. (2008) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2008.00331.x · Cited by 242
Joint Effects of Body Weight and Alcohol on Elevated Serum Alanine Aminotransferase in the United States Population
Ruhl, C. E., & Everhart, J. E. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00743-3 · Cited by 242
Childhood obesity and the associated rise in cardiometabolic complications
Caprio, S., Santoro, N., & Weiss, R. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0183-z · Cited by 242
A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis
Schwimmer, J. B., Middleton, M. S., Deutsch, R., & Lavine, J. E. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02420.x · Cited by 242
Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis
Wu, J. W., Wang, S. P., Álvarez, F., Casavant, S., Gauthier, N., Abed, L., Soni, K. G., Yang, G., & Mitchell, G. A. (2011) · Hepatology · doi:10.1002/hep.24338 · Cited by 241
Non‐alcoholic fatty liver disease ( NAFLD ) is associated with low level of physical activity: a population‐based study
Gerber, L. H., Otgonsuren, M., Mishra, A., Escheik, C., Birerdinc, A., Stepanova, M., & Younossi, Z. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12038 · Cited by 240
Prevalence of fatty liver disease and its risk factors in the population of South China
Zhou, Y. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i47.6419 · Cited by 240
Change in Liver Size and Fat Content after Treatment with Optifast® Very Low Calorie Diet
Lewis, M., Phillips, M., Slavotinek, J., Kow, L., Thompson, C. H., & Toouli, J. (2006) · Obesity Surgery · doi:10.1381/096089206777346682 · Cited by 239
Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases
van der Heide, D., Weiskirchen, R., & Bansal, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02852 · Cited by 239
Nonalcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-Aged Japanese Men
Shibata, M., Kihara, Y., Taguchi, M., Tashiro, M., & Otsuki, M. (2007) · Diabetes Care · doi:10.2337/dc07-0792 · Cited by 238
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome
Basantani, M. K., Sitnick, M. T., Cai, L., Brenner, D., Gardner, N. P., Li, J. Z., Schoiswohl, G., Yang, K., Kumari, M., Gross, R. W., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m011205 · Cited by 238
Fatty Acid–Regulated Transcription Factors in the Liver
Jump, D. Β., Tripathy, S., & Depner, C. M. (2013) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161139 · Cited by 238
Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 238
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
Scorletti, E., Afolabi, P. R., Miles, E. A., Smith, D. E., Almehmadi, A., Alshathry, A., Childs, C. E., Del Fabbro, S., Bilson, J., Moyses, H. E., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.031 · Cited by 237
Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease
Targher, G., Chonchol, M., Bertolini, L., Rodella, S., Zenari, L., Lippi, G., Franchini, M., Zoppini, G., & Muggeo, M. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101155 · Cited by 236
Trimethylamine N ‐Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease
Tan, X., Liu, Y., Long, J., Chen, S., Liao, G., Wu, S., Li, C., Wang, L., Ling, W., & Zhu, H. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900257 · Cited by 236
Fructose as a key player in the development of fatty liver disease
Basaranoglu, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i8.1166 · Cited by 235
An assessment by the Statin Liver Safety Task Force: 2014 update
Bays, H. E., Cohen, D. E., Chalasani, N., & Harrison, S. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.011 · Cited by 235
Apigenin, a modulator of PPARγ, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation
Feng, X., Yu, W., Li, X., Zhou, F., Zhang, W., Shen, Q., Li, J., Zhang, C., & Shen, P. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.04.014 · Cited by 235
The Role of Cytokines in Non-Alcoholic Fatty Liver Disease
Tilg, H. (2010) · Digestive Diseases · doi:10.1159/000282083 · Cited by 234
Metabolic syndrome and non-alcoholic fatty liver disease
Almeda‐Valdés, P., Ramos, D. C., & Aguilar-Salinas, C. A. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31822-8 · Cited by 234
Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region?
Farrell, G. C. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02989.x · Cited by 234
Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non‐alcoholic steatohepatitis
Farhadi, A., Gundlapalli, S., Shaikh, M. W., Frantzides, C. T., Harrell, L. E., Kwasny, M., & Keshavarzian, A. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01723.x · Cited by 233
Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion
Pettinelli, P., del Pozo, T., Julia Araya, A., Rodrigo, R., Araya, A. V., Smok, G., Csendes, A., Gutiérrez, L., Rojas, J., Owen Korn, B., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.015 · Cited by 233
Pathogenesis of nonalcoholic steatohepatitis
Liu, W., Baker, R. D., Bhatia, T., Zhu, L., & Baker, S. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2161-x · Cited by 233
Liver Transplantation for Nonalcoholic Steatohepatitis
Agopian, V. G., Kaldas, F. M., Hong, J. C., Whittaker, M., Holt, C., Rana, A. A., Zarrinpar, A., Petrowsky, H., Farmer, D. G., Yersiz, H., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826b4b7e · Cited by 233
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Paschou, S. Α., Pοlyzos, S. A., Anagnostis, P. G., Goulis, D. G., Kanaka‐Gantenbein, C., Lambrinoudaki, I. V., Georgopoulos, N. A., & Vryonidou, A. (2019) · Endocrine · doi:10.1007/s12020-019-02085-7 · Cited by 233
Cellular Mechanisms by Which FGF21 Improves Insulin Sensitivity in Male Mice
Camporez, J. P., Jornayvaz, F. R., Petersen, M. C., Pesta, D. H., Guigni, B. A., Serr, J., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1191 · Cited by 232
Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression
Barr, J., Caballería, J., Martínez‐Arranz, I., Domínguez‐Díez, A., Alonso, C., Muntané, J., Pérez-Cormenzana, M., García‐Monzón, C., Mayo, R., Martín‐Duce, A., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr201223p · Cited by 229
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P. (2005) · Hepatology · doi:10.1002/hep.20672 · Cited by 228
Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression
Zhou, D., Chen, Y., Zhao, Z., Yang, R., Xin, F., Liu, X., Pan, Q., Zhou, H., & Fan, J. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0183-1 · Cited by 228
Insulin Resistance Accelerates a Dietary Rat Model of Nonalcoholic Steatohepatitis
Ota, T., Takamura, T., Kurita, S., Matsuzawa, N., Kita, Y., Uno, M., Akahori, H., Misu, H., Sakurai, M., Zen, Y., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.10.014 · Cited by 227
Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease
Chang, Y., Ryu, S., Sung, E., & Jang, Y. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081257 · Cited by 227
Metabolic Effects of Thyroid Hormone Derivatives
Moreno, M., de Lange, P., Lombardi, A., Silvestri, E., Lanni, A., & Goglia, F. (2008) · Thyroid · doi:10.1089/thy.2007.0248 · Cited by 226
Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome
Mohan, V., Syed, F., Deepa, M., Ravikumar, R., & Pitchumoni, C. S. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.11.039 · Cited by 226
Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446575 · Cited by 225
Computed Tomography Scans in the Evaluation of Fatty Liver Disease in a Population Based Study
Zeb, I., Li, D., Nasir, K., Katz, R., Larijani, V. N., & Budoff, M. J. (2012) · Academic Radiology · doi:10.1016/j.acra.2012.02.022 · Cited by 225
The Roles of Leptin and Adiponectin
Ding, X., Saxena, N. K., Lin, S., Xu, A., Srinivasan, S., & Anania, F. A. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62476-5 · Cited by 225
Obesity and diabetes as a risk factor for hepatocellular carcinoma
Regimbeau, J. M., Colombat, M., Mognol, P., Durand, F., Abdalla, E. K., Degott, C., Degos, F., Farges, O., & Belghiti, J. (2004) · Liver Transplantation · doi:10.1002/lt.20033 · Cited by 225
Association of Nonalcoholic Fatty Liver Disease With Components of Metabolic Syndrome According to Body Mass Index in Korean Adults
Kwon, Y.-M., Oh, S., Hwang, S.-S., Lee, C. M., Kwon, H., & Chung, G. E. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.314 · Cited by 225
Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice
Leclercq, I. A., Farrell, G. C., Sempoux, C. L., Peňa, A. D., & Horsmans, Y. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.010 · Cited by 225
Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts
Ma, J., Fox, C. S., Jacques, P. F., Speliotes, E. K., Hoffmann, U., Smith, C. E., Saltzman, E. J., & McKeown, N. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.032 · Cited by 224
The Impact of Obesity on Long-term Outcomes in Liver Transplant Recipients—Results of the NIDDK Liver Transplant Database
Leonard, J., Heimbach, J. K., Malinchoc, M., Watt, K. D. S., & Charlton, M. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02100.x · Cited by 224
PFOS-induced hepatic steatosis, the mechanistic actions on β-oxidation and lipid transport
Wan, H. T., Zhao, Y. G., Wei, X., Hui, K. Y., Giesy, J. P., & Wong, C. K. C. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.03.010 · Cited by 224
Fructose-Induced Fatty Liver Disease
Ackerman, Z., Oron‐Herman, M., Grozovski, M., Rosenthal, T., Pappo, O., Link, G., & Sela, B. (2005) · Hypertension · doi:10.1161/01.hyp.0000164570.20420.67 · Cited by 223
Obesity and Nonalcoholic Fatty Liver Disease
Angulo, P. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00329.x · Cited by 222
Self-citation
Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: The significance of dietary cholesterol
Yasutake, K., Nakamuta, M., Shima, Y., Ohyama, A., Masuda, K., Haruta, N., Fujino, T., Aoyagi, Y., Fukuizumi, K., Yoshimoto, T., et al. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802588133 · Cited by 222
Lipid-Induced Hepatocyte-Derived Extracellular Vesicles Regulate Hepatic Stellate Cells via MicroRNA Targeting Peroxisome Proliferator-Activated Receptor-γ
Povero, D., Panera, N., Eguchi, A., Johnson, C. D., Papouchado, B. G., de Araujo Horcel, L., Pinatel, E. M., Alisi, A., Nobili, V., & Feldstein, A. E. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.07.007 · Cited by 221
The liver in celiac disease
Rubio‐Tapia, A., & Murray, J. A. (2007) · Hepatology · doi:10.1002/hep.21949 · Cited by 219
A Common Variant in the Patatin-Like Phospholipase 3 Gene ( PNPLA3 ) Is Associated with Fatty Liver Disease in Obese Children and Adolescents
Santoro, N., Kursawe, R., D’Adamo, E., Dykas, D. J., Zhang, C. K., Bale, A. E., Cali, A. M. G., Narayan, D., Shaw, M. M., Pierpont, B. M., et al. (2010) · Hepatology · doi:10.1002/hep.23832 · Cited by 219
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame
Ibrahim, S. H., Hirsova, P., Malhi, H., & Gores, G. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3977-1 · Cited by 218
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Prashanth, M., Ganesh, H. K., Vima, M. V., John, M., Bandgar, T., Joshi, S., Shah, S., Rathi, P. M., Joshi, A. S., Thakkar, H. U., et al. (2009) · PubMed · Cited by 217
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine #
Lee, L., Alloosh, M., Saxena, R., Alstine, W. V., Watkins, B. A., Klaunig, J. E., Sturek, M. S., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.22904 · Cited by 217
Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients: Another Story of “Seed and Soil”
Dumortier, J., Giostra, E., Belbouab, S., Morard, I., Guillaud, O., Spahr, L., Boillot, O., Rubbia‐Brandt, L., Scoazec, J., & Hadengue, A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.717 · Cited by 216

Authors: Angulo, P.
Affiliations: Mayo Clinic (US)
Corresponding author: Angulo, Paul
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2002-04-18
Volume: 346
Issue: 16
Pages: 1221-1231
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra011775
OpenAlex: W2040109162
Cited by: 5,228
References: 90
Citations by year: 2026: 38 · 2025: 80 · 2024: 102 · 2023: 171 · 2022: 155 · 2021: 191 · 2020: 246 · 2019: 228 · 2018: 222 · 2017: 264 · 2016: 275 · 2015: 339 · 2014: 368 · 2013: 319 · 2012: 309
FWCI: 23.15
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: non-alcoholic fatty liver disease, hepatic steatosis, steatohepatitis, liver fibrosis, liver cirrhosis, obesity, type 2 diabetes, hyperlipidemia, risk factors, alcohol abuse
MeSH terms: Biopsy, Fatty Liver, Humans, Liver, Liver Function Tests, Radiography, Risk Factors, Ultrasonography, Weight Loss, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nonalcoholic Fatty Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks